Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.44 Billion CNY | -1.1% |
| 2022 | 4.44 Billion CNY | 17.94% |
| 2021 | 3.76 Billion CNY | 26.45% |
| 2020 | 2.97 Billion CNY | 11.15% |
| 2019 | 2.67 Billion CNY | 38.85% |
| 2018 | 1.92 Billion CNY | 37.82% |
| 2017 | 1.4 Billion CNY | 42.84% |
| 2016 | 980.22 Million CNY | 36.81% |
| 2015 | 716.48 Million CNY | 27.2% |
| 2014 | 563.29 Million CNY | 37.6% |
| 2013 | 409.36 Million CNY | 28.67% |
| 2012 | 318.14 Million CNY | 50.18% |
| 2011 | 211.84 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 1.17 Billion CNY | 5.95% |
| 2024 Q1 | 1.07 Billion CNY | -9.26% |
| 2024 Q2 | 1.1 Billion CNY | 2.66% |
| 2023 Q3 | 1.13 Billion CNY | 5.89% |
| 2023 Q4 | 1.18 Billion CNY | 4.74% |
| 2023 Q1 | 1.03 Billion CNY | -10.66% |
| 2023 FY | 4.39 Billion CNY | -1.1% |
| 2023 Q2 | 1.07 Billion CNY | 3.38% |
| 2022 Q4 | 1.16 Billion CNY | -4.22% |
| 2022 Q3 | 1.21 Billion CNY | 16.57% |
| 2022 Q1 | 1.03 Billion CNY | -3.69% |
| 2022 FY | 4.44 Billion CNY | 17.94% |
| 2022 Q2 | 1.03 Billion CNY | 0.77% |
| 2021 Q3 | 1.01 Billion CNY | 18.25% |
| 2021 FY | 3.76 Billion CNY | 26.45% |
| 2021 Q1 | 817 Million CNY | -12.22% |
| 2021 Q2 | 860.58 Million CNY | 5.33% |
| 2021 Q4 | 1.07 Billion CNY | 5.21% |
| 2020 Q3 | 841.56 Million CNY | 28.4% |
| 2020 FY | 2.97 Billion CNY | 11.15% |
| 2020 Q1 | 550.37 Million CNY | -29.96% |
| 2020 Q2 | 655.4 Million CNY | 19.08% |
| 2020 Q4 | 930.79 Million CNY | 10.6% |
| 2019 Q3 | 714.26 Million CNY | 13.12% |
| 2019 Q2 | 631.39 Million CNY | 15.23% |
| 2019 FY | 2.67 Billion CNY | 38.85% |
| 2019 Q4 | 785.8 Million CNY | 10.02% |
| 2019 Q1 | 547.96 Million CNY | -3.78% |
| 2018 Q3 | 511.9 Million CNY | 18.3% |
| 2018 Q4 | 569.47 Million CNY | 11.25% |
| 2018 FY | 1.92 Billion CNY | 37.82% |
| 2018 Q1 | 415.59 Million CNY | -0.4% |
| 2018 Q2 | 432.7 Million CNY | 4.12% |
| 2017 Q3 | 400.37 Million CNY | 17.51% |
| 2017 FY | 1.4 Billion CNY | 42.84% |
| 2017 Q4 | 417.24 Million CNY | 4.21% |
| 2017 Q1 | 241.8 Million CNY | -16.02% |
| 2017 Q2 | 340.71 Million CNY | 40.9% |
| 2016 Q1 | 192.17 Million CNY | -6.4% |
| 2016 Q3 | 258.54 Million CNY | 7.03% |
| 2016 Q4 | 287.94 Million CNY | 11.37% |
| 2016 Q2 | 241.56 Million CNY | 25.7% |
| 2016 FY | 980.22 Million CNY | 36.81% |
| 2015 Q1 | 156.41 Million CNY | 0.0% |
| 2015 Q3 | 198.34 Million CNY | 26.81% |
| 2015 Q4 | 205.31 Million CNY | 3.52% |
| 2015 FY | 716.48 Million CNY | 27.2% |
| 2015 Q2 | 156.41 Million CNY | 0.0% |
| 2014 FY | 563.29 Million CNY | 37.6% |
| 2013 FY | 409.36 Million CNY | 28.67% |
| 2012 FY | 318.14 Million CNY | 50.18% |
| 2011 FY | 211.84 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 9.14 Billion CNY | 51.422% |
| Joinn Laboratories(China)Co.,Ltd. | 2.37 Billion CNY | -86.984% |
| WuXi AppTec Co., Ltd. | 40.04 Billion CNY | 88.903% |
| Thalys Medical Technology Group Inc. | 2 Billion CNY | -121.503% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 8.53 Billion CNY | 47.964% |
| Chemclin Diagnostics Co., Ltd. | 445.34 Million CNY | -897.81% |